國家衛生研究院 NHRI:Items for Author

Year

Loading year class tree, please wait....

Collection	Date	Title	Relation
[陳立宗] 期刊論文	2024-08	Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study	-
[陳立宗] 期刊論文	2023-11	Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer	-
[陳立宗] 期刊論文	2023-07	Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462	-
[陳立宗] 會議論文/會議摘要	2022-11	Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)	-
[陳立宗] 會議論文/會議摘要	2022-09	Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)	-
[陳立宗] 會議論文/會議摘要	2022-02-01	A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1	-